Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical
phase III trial which tests if the median progression-free survival (PFS) of patients with
newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of
intraoperative radiotherapy (IORT) to standard radiochemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Universitätsmedizin Mannheim
Collaborators:
Canarian Institute for Cancer Research, Las Palmas Carl Zeiss Meditec AG Catalan Institute of Oncology, Barcelona Loyola University Chicago Montreal Neurological Institute and Hospital National Institute of Neoplastic Diseases (INEN), Lima The Cleveland Clinic University of California, Los Angeles University of Notre Dame Australia